PRESS RELEASE published on 06/07/2024 at 17:45, 2 years 4 months ago Changes in the rights attaching to the classes of shares or securities Median Technologies discloses total voting rights and share capital as of May 31, 2024, in compliance with French regulations. The company specializes in AI-driven solutions for cancer diagnosis and treatment Share Capital Voting Rights AI Solutions Median Technologies Cancer Diagnosis
PRESS RELEASE published on 06/07/2024 at 17:45, 2 years 4 months ago Modification des droits attachés aux catégories d'actions Déclaration du nombre de droits de vote et d'actions de Median Technologies au 31 mai 2024. Découvrez les chiffres clés de l'entreprise et ses activités dans l'imagerie médicale et l'IA Euronext Growth Imagerie Médicale Intelligence Artificielle Oncologie Median Technologies
BRIEF published on 05/29/2024 at 17:50, 2 years 5 months ago Median Technologies to Attend 2024 ASCO Annual Meeting in Chicago Clinical Trials Oncology Imaging Solutions Median Technologies ASCO Annual Meeting
BRIEF published on 05/29/2024 at 17:50, 2 years 5 months ago Median Technologies participera à la réunion annuelle de l'ASCO 2024 à Chicago Solutions D'imagerie Essais Cliniques Oncologie Technologies Médianes Réunion Annuelle De L'ASCO
PRESS RELEASE published on 05/29/2024 at 17:45, 2 years 5 months ago Inside Information / Other news releases Median Technologies to participate in the 2024 ASCO Annual Meeting at McCormick Place, Chicago, IL, USA. Abstract on double reading performance in lung clinical trials. Event details and company overview Clinical Trials Oncology Medical Imaging Median Technologies ASCO Annual Meeting
BRIEF published on 05/21/2024 at 17:50, 2 years 5 months ago Median Technologies renforce sa position auprès des géants pharmaceutiques Imagerie Médicale Intelligence Artificielle Essais Cliniques Oncologie Median Technologies
BRIEF published on 05/21/2024 at 17:50, 2 years 5 months ago Median Technologies strengthens its position with pharmaceutical giants Artificial Intelligence Oncology Medical Imaging Median Technologies Clinical Tests
PRESS RELEASE published on 05/21/2024 at 17:45, 2 years 5 months ago Informations privilégiées / Autres communiqués Median Technologies devient fournisseur privilégié d'un nouveau laboratoire pharmaceutique du Top 3 mondial, renforçant ainsi sa position de leader en services d'imagerie pour les essais cliniques en oncologie Oncologie Median Technologies Laboratoire Pharmaceutique Services D'imagerie Accord-cadre De Services
BRIEF published on 05/10/2024 at 17:50, 2 years 5 months ago Median Technologies Announces Update on Shares Voting Rights Voting Rights Median Technologies Share Structure French Corporate Law Non-voting Shares
BRIEF published on 05/10/2024 at 17:50, 2 years 5 months ago Median Technologies annonce une mise à jour sur les droits de vote des actions Droit De Vote Technologies Médianes Structure De Partage Droit Des Sociétés Français Actions Sans Droit De Vote
Published on 10/29/2026 at 22:01, 14 hours 7 minutes ago Pinetree Capital Announces Unaudited Financial Results for the Period Ended September 30, 2026
Published on 10/29/2026 at 21:30, 14 hours 38 minutes ago Shelfie Announces Amendments to Previously Announced Acquisition of Aspect
Published on 10/29/2026 at 18:30, 17 hours 38 minutes ago Kidoz Inc. Appoints Derek Sentner as Chief Revenue Officer
Published on 10/29/2026 at 16:05, 20 hours 3 minutes ago SouthGobi Announces Date of Special Meeting of Shareholders and The Record Date
Published on 10/30/2026 at 11:30, 38 minutes ago BROADPEAK SA: Mise à disposition du Rapport Financier Semestriel 2026
Published on 10/30/2026 at 11:05, 1 hour 3 minutes ago Cambrex Breaks Ground on $120 Million Expansion in Charles City, Iowa
Published on 10/30/2026 at 11:05, 1 hour 3 minutes ago Cognizant commits more than 25,000 professionals to OpenAI delivery as enterprises move frontier AI into production
Published on 10/30/2026 at 10:50, 1 hour 18 minutes ago Triskell Software unveils new AI capabilities in its 2026 SP2 Release
Published on 10/30/2026 at 12:00, 8 minutes ago Kapitaalverhoging door uitoefening van inschrijvingsrechten
Published on 10/30/2026 at 12:00, 8 minutes ago Capital increase through exercise of subscription rights
Published on 10/30/2026 at 08:00, 4 hours 8 minutes ago Neoen secures AUD 1.8 billion in debt financing to support renewable energy portfolio in Australia
